Merit Medical Systems (MMSI) has provided an update.
On July 1, 2024, Merit successfully acquired the EsophyX® Z+ device and related assets from EndoGastric Solutions, Inc. for $105 million, expanding its portfolio into non-pharmacological treatments for gastroesophageal reflux disease. This strategic acquisition, financed through Merit’s long-term credit facility, also included the assumption or reimbursement of certain liabilities and was backed by a buyer-side representation and warranty insurance policy. Following the deal, Merit signed additional agreements ensuring a smooth transition of the business operations and assets.
Learn more about MMSI stock on TipRanks’ Stock Analysis page.
